Core Viewpoint - On October 16, Jiuan Medical experienced a 1.29% increase in stock price with a trading volume of 537 million yuan, indicating strong market interest and activity in the company's shares [1]. Financing Summary - On October 16, Jiuan Medical had a financing purchase amount of 63.86 million yuan and a financing repayment of 55.10 million yuan, resulting in a net financing purchase of 8.76 million yuan. The total financing and securities balance reached 1.21 billion yuan [1]. - The current financing balance of 1.20 billion yuan accounts for 6.34% of the circulating market value, which is above the 80th percentile level over the past year, indicating a high level of financing activity [1]. - In terms of securities lending, Jiuan Medical repaid 2,000 shares and sold 5,000 shares on October 16, with a selling amount of 203,900 yuan. The remaining securities lending volume is 244,300 shares, with a balance of 9.96 million yuan, also exceeding the 90th percentile level over the past year [1]. Business Performance - As of September 19, Jiuan Medical had 72,000 shareholders, a decrease of 1.50% from the previous period, while the average circulating shares per person increased by 1.53% to 6,582 shares [2]. - For the first half of 2025, Jiuan Medical reported a revenue of 765 million yuan, a year-on-year decrease of 43.35%, while the net profit attributable to the parent company was 920 million yuan, reflecting a year-on-year increase of 52.91% [2]. Dividend and Shareholding Structure - Since its A-share listing, Jiuan Medical has distributed a total of 1.794 billion yuan in dividends, with 1.39 billion yuan distributed over the past three years [3]. - As of June 30, 2025, among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF held 10.99 million shares, a decrease of 1.836 million shares from the previous period. The Southern Zhongzheng 500 ETF held 4.936 million shares, down by 128,100 shares. Hong Kong Central Clearing Limited entered the top ten shareholders with 2.7895 million shares [3].

Core Viewpoint - The company, Jiann Medical (九安医疗), has announced that it will disclose its Q3 2025 financial report on October 25, 2025, and has not provided any preliminary performance forecasts for the current quarter [1] Group 1 - Investors inquired about the performance comparison of Q3 2025 with the same period last year, specifically whether there was growth or decline [1] - Jiann Medical confirmed the scheduled disclosure date for its Q3 2025 report, indicating that detailed operational and financial information will be available at that time [1]

公司 2024 年员工持股计划管理委员会委员施向健先生因个人原因，申请辞 去管理委员会委员职务。根据公司《2024 年员工持股计划管理办法》的相关规 定，本次持有人会议同意补选马志国先生为公司 2024 年员工持股计划管理委员 会委员，任期与本次员工持股计划存续期一致。 马志国先生未在公司担任董事、监事、高级管理人员职务，未在公司第一大 股东单位担任职务，与持有公司 5%以上股东、实际控制人、公司董事、监事、 高级管理人员不存在关联关系。 证券代码：002432 证券简称：九安医疗 公告编号：2025-080 天津九安医疗电子股份有限公司 2024年员工持股计划第二次持有人会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）于 2025 年 10 月 15 日 在公司会议室以现场结合通讯方式召开 2024 年员工持股计划第二次持有人会议。 本次会议通知已于 2025 年 10 月 11 日以通讯方式发出。本次会议由公司 2024 年员工持股计划管理委员会召集，由管理委员会主任张飞先生主持。本次应参会 持 ...

Core Viewpoint - The Shanghai Composite Index closed at 3916.23 points, above the annual line, with a slight increase of 0.10% on the day, and the total trading volume of A-shares reached 1,948.66 billion yuan [1][2] Group 1: Market Performance - As of the latest close, 19 A-shares have surpassed the annual line, indicating positive market sentiment [1] - The stocks with the largest deviation rates include Shenglong Co., Changshan Beiming, and Youlide, with deviation rates of 9.96%, 3.76%, and 2.52% respectively [1] - The total trading volume for A-shares today was 1,948.66 billion yuan, reflecting active market participation [1] Group 2: Individual Stock Highlights - Shenglong Co. (603178) saw a daily increase of 10.00% with a turnover rate of 9.13% and a latest price of 21.45 yuan, resulting in a deviation rate of 9.96% [1] - Changshan Beiming (000158) increased by 9.98% with a turnover rate of 9.68%, latest price at 24.57 yuan, and a deviation rate of 3.76% [1] - Youlide (688628) experienced a 4.23% increase, with a turnover rate of 2.91%, latest price of 36.22 yuan, and a deviation rate of 2.52% [1]

Market Overview - The Shanghai Composite Index is at 3916.86 points, above the annual line, with a change of 0.12% [1] - The total trading volume of A-shares is 909.4 billion yuan [1] Stocks Breaking Annual Line - A total of 20 A-shares have surpassed the annual line today, with notable stocks including: - Shenglong Co., Ltd. (603178) with a deviation rate of 9.96% - Lege Co., Ltd. (300729) with a deviation rate of 2.14% - Jinguang Co., Ltd. (300510) with a deviation rate of 1.75% [1] Deviation Rate Rankings - The following stocks have the highest deviation rates after breaking the annual line: - Shenglong Co., Ltd. (603178): Today's change of 10.00%, turnover rate of 4.72%, latest price at 21.45 yuan [1] - Lege Co., Ltd. (300729): Today's change of 4.01%, turnover rate of 4.10%, latest price at 15.58 yuan [1] - Jinguang Co., Ltd. (300510): Today's change of 2.00%, turnover rate of 5.62%, latest price at 4.60 yuan [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the annual line include: - Changjiang Electric Power (600900): Today's change of 0.36%, latest price at 28.03 yuan, deviation rate of 0.01% [2] - Beiqi Blue Valley (600733): Today's change of 3.05%, latest price at 8.11 yuan, deviation rate of 0.03% [2] - Hongcheng Environment (600461): Today's change of 0.22%, latest price at 9.10 yuan, deviation rate of 0.05% [2]

Core Insights - On October 16, 17 companies announced a total of 17 stock repurchase updates, indicating a significant activity in the market [1] Group 1: First Disclosure of Repurchase Plans - Three companies disclosed their stock repurchase plans for the first time, with proposed repurchase amounts of up to 400 million yuan, 150 million yuan, and 100 million yuan respectively for Hengmingda, Qizhong Technology, and Kangchen Pharmaceutical [1] Group 2: Approval of Repurchase Plans by Shareholders - Five companies had their repurchase plans approved by shareholder meetings, with the highest proposed repurchase amounts being 150 million yuan for Fenghuo Communication, 70 million yuan for Shaanxi Jinye, and 10 million yuan for Youkede-W [1] Group 3: Progress of Implemented Repurchase Plans - Four companies reported on the progress of their repurchase plans, with the highest repurchase amounts being 37.86 million yuan for Jiuan Medical, 11.19 million yuan for Intercontinental Oil and Gas, and 3.09 million yuan for Jiansheng Group [1] Group 4: Completed Repurchase Plans - Five companies completed their repurchase plans, with the highest completed amounts being 797 million yuan for Zhongwei Co., 200 million yuan for Shuangta Food, and 7.5177 million yuan for Shapais [1]

证券日报网讯10月15日晚间，九安医疗（002432）发布公告称，2025年10月15日，公司首次通过股份回 购专用证券账户以集中竞价方式回购公司股份946，400股，占公司目前总股本0.20%。 ...

Core Viewpoint - Tianjin Jiuan Medical Electronics Co., Ltd. has initiated its share repurchase plan, marking a significant step in its financial strategy [1][2]. Group 1: Share Repurchase Details - On October 15, 2025, the company completed its first share repurchase, acquiring 946,400 shares, which represents 0.20% of its total share capital, for a total transaction amount of 37.86 million yuan [1][2]. - The board approved a share repurchase plan on October 13, 2025, with a total funding of no less than 300 million yuan and no more than 600 million yuan, and a maximum repurchase price of 53.5 yuan per share [2]. Group 2: Compliance and Future Disclosures - The company will disclose the share repurchase details on the trading day following the repurchase, in accordance with regulatory guidelines [3]. - Jiuan Medical has committed to not conducting repurchases during periods that could affect stock prices due to significant events, adhering to regulations set by the China Securities Regulatory Commission and Shenzhen Stock Exchange [3].

Core Viewpoint - Jiuan Medical (002432.SZ) has announced a share buyback plan, indicating confidence in its stock value and commitment to returning capital to shareholders [1] Group 1: Share Buyback Details - The company repurchased 946,400 shares, which represents 0.20% of its total share capital [1] - The highest transaction price was 40.10 CNY per share, while the lowest was 39.83 CNY per share [1] - The total transaction amount was 37,860,778.00 CNY, excluding transaction fees [1] Group 2: Compliance and Strategy - The buyback is in accordance with relevant laws and regulations [1] - The action aligns with the company's established share repurchase plan [1]

Group 1 - Company announced a share buyback plan on October 15, 2023, intending to repurchase approximately 950,000 shares, which represents 0.2% of the total share capital [1] - The buyback will be conducted through a centralized bidding method, with a maximum transaction price of 40.1 CNY per share and a minimum transaction price of 39.83 CNY per share [1] - The total transaction amount for the buyback is approximately 37.86 million CNY [1] Group 2 - The news highlights a significant opportunity in the silver market, with annualized interest rates soaring to 35% [1] - There is a global trend of silver being airlifted to the UK for profit, indicating a major market event [1] - This situation is described as an epic short squeeze, suggesting potential volatility and investment opportunities in the silver industry [1]